The Drug Science Podcast 133. Psychedelic Ethics with Dr Edward Jacobs and Sam Bloomfield
Aug 6, 2025
Sam Bloomfield, founder of PsyEdu and psychotherapist, and Dr. Edward Jacobs, a pioneer in psychedelic ethics, dive deep into the evolving landscape of psychedelics. They discuss the critical need for ethical guidelines in psychedelic trials and the importance of education for health professionals. Bloomfield highlights the role of structured retreats, while Jacobs emphasizes participant autonomy. They also explore the impact of public perception on policy reform and advocate for inclusivity to ensure equitable access to psychedelic therapies.
AI Snips
Chapters
Transcript
Episode notes
Psychedelic Benefits Beyond Symptoms
- Many psychedelic trial participants value connection and meaning more than symptom remission.
- This highlights the unique, holistic impact of psychedelics beyond clinical endpoints.
Psychological Growth Over Cure
- Participants cherish the psychological growth psychedelics enable more than just symptom relief.
- This highlights the deeper psychological transformation psychedelics promote beyond medical goals.
Post-Trial Psychedelic Use Reality
- Psilocybin trial participants often seek illegal or risky access after trials due to treatment gaps.
- Ethical oversight must consider and mitigate this post-trial behavior for participant safety.